OBSN Obseva

ObsEva SA to Hold Conference Call to Discuss PRIMROSE 2 Trial Results on December 9, 2019

ObsEva SA to Hold Conference Call to Discuss PRIMROSE 2 Trial Results on December 9, 2019

 

Geneva, Switzerland and Boston, MA –December 6, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that it will release results from the Phase 3 PRIMROSE 2 clinical trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids, on Monday  December 9, 2019.  ObsEva management will host an investment community conference call at 8 a.m. Eastern Time, 2 p.m. Central European Time, Monday December 9, 2019, to discuss these results. 

Investors may participate by dialing (844) 419-1772 for U.S. callers or +1 (213) 660-0921 for international callers, and referring to conference ID 1764134.  A webcast of the conference call can be accessed under the “Investors” section of ObsEva’s website .

About ObsEva

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit .

 

For further information, please contact:

 

Media Contact Switzerland and Europe:

Christophe Lamps

Dynamics Group



Office

7 Mobile

Media Contact U.S.:

Marion Janic

RooneyPartners LLC



Office

Mobile

CEO Office Contact:

Shauna Dillon



Investor Contact:

Mario Corso

Senior Director, Investor Relations



Office

Mobile

 

 

 

Attachment

EN
06/12/2019

Underlying

OBSNObseva

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Obseva

 PRESS RELEASE
Free
OBSN OBSEVA

ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from ...

ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that the Regulatory Board of SIX Swiss Exchange has granted the delisting of the shares of the company (Swiss Security Number 126'004'193 / ISIN CH1260041939) from SIX Swiss Exchange and has exempted the company from certai...

April 3, 2024 1 EN
 PRESS RELEASE
Free
OBSN OBSEVA

ObsEva Announces Update on Board of Directors

ObsEva Announces Update on Board of Directors Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that, concurrent to the decision to wind-down the company’s operations, Catarina Edfjäll, Ph.D. has decided to step down from the Board effective today. “We would like to warmly thank Catarina for her significant contribution to the company over the last years. We are grateful to have had the opportunity...

March 19, 2024 1 EN
 PRESS RELEASE
Free
OBSN OBSEVA

ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will...

ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023 Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it will wind-down its operations with the termination of all of its employees, including Fabien de Ladonchamps, CEO, and notified SIX Swiss Exchange's listing authority that there was a substantial risk that it will lack ...

February 28, 2024 1 EN
 PRESS RELEASE
Free
OBSN OBSEVA

Geneva Court Grants Temporary Moratorium to ObsEva

Geneva Court Grants Temporary Moratorium to ObsEva Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 31 January 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it was granted a temporary moratorium (sursis provisoire) by the competent court in Geneva, Switzerland. The Tribunal de première instance of Geneva granted the requested moratorium for a period of four months ending 29 May 2024 and appointed a commissioner (commissaire) to supervise the company's activities durin...

January 31, 2024 1 EN
 PRESS RELEASE
Free
OBSN OBSEVA

ObsEva Announces Application for a Moratorium to Facilitate Pivotal De...

ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – November 30, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that, following a comprehensive assessment of the company's financial position, the Board of Directors has opted to seek a moratorium from the competent court in Geneva, Switzerland. The moratorium, if granted, will provide essential protection, enabling the company to focus on negotiations and...

November 30, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch